ClinicalTrials.gg
CompletedNCT00686335MONAUpdated Dec 17, 2024Results posted

A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma

A Phase 2 interventional study of Lodotra and Cortancyl in Asthma, sponsored by Amgen. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing prednisone in Asthma — 2 open to participants now, 2 under way, none of them phase 3. Prednisone · Asthma.

Enrollment
9th of 11
12 · median 40
Started
2008
with 1 other
Phase 2
Only one
of the 11
Registered
4th of 11
by date
Lead sponsor
1 of 11
Amgen

Among the 11 studies testing prednisone in Asthma, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is the only one in phase 2, and was the 4th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 11 studies testing prednisone in Asthma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About prednisone

Prednisone: first FDA approval 1955 (METICORTEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing prednisone in Asthma, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms.

Read the detailed description

Study with completed results acquired from Horizon in 2024.

03

Conditions studied

  • Asthma

Keywords

  • asthma
  • nocturnal asthma
  • glucocorticoid dependent persistent asthma
  • signs and symptoms
  • lung function
  • prednisone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must be able to understand the terms of the written form, and must provide a dated and signed form before the start of any study procedure
  • At least 18 years old
  • Patient having a diagnosis of asthma dating back more than 6 months at the time of inclusion
  • Asthma necessitating a continuous treatment by oral corticoids
  • A minimum of 3 nocturnal awakenings due to asthma during the last screening week
  • Stable dose of oral for at least 4 weeks prior to inclusion into the study
  • No change in asthma medication during the last 4 weeks prior to V0
  • Non-smoker or ex-smoker (having stopped smoking more than one year previously and with a smoking history of less than 10 pack years )
  • Female patients of must be using a medically accepted regimen
  • Able to perform the required study procedures including handling of medication containers and diaries

Exclusion criteria

Exclusion Criteria:

  • Poorly controlled asthma, defined as meeting at least one of the following within the 4 weeks prior to Visit V0:

    • hospital admission for asthma (including treatment in an emergency room),
    • a lower airway infection,
  • Diagnosis of or other relevant lung diseases (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, active tuberculosis, interstitial lung disease)
  • abnormalities of the hematological or biochemical constants
  • Pregnancy or breastfeeding
  • Participation in another clinical study within 30 days preceding Visit V0,
  • Re-entry of patients previously enrolled in this trial,
  • Suspected inability or unwillingness to comply with the study procedures
  • Alcohol or drug abuse
  • Need to take a non-authorised concomitant treatment (cf. list of medicaments not authorised during the study) in the course of the study
  • Other disease requiring treatment with
  • Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
  • Patient with a hospitalisation scheduled during the study period
  • Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension, etc.)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Lodotra

    After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.

    Drug: Lodotra

  • Active comparator
    Cortancyl

    During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.

    Drug: Cortancyl

Interventions

  • Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.

    Also known as: modified release tablet formulation of prednisone

  • Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).

    Also known as: immediate release prednisone tablets

06

What researchers measure

Primary outcomes

  1. Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment

    Variation in the total number of nocturnal awakenings during the last 2 weeks of run-in treatment with Cortancyl and the last 2 weeks of treatment with Lodotra.

    Time frame: 4 weeks and 8 weeks

07

Results

Posted Dec 28, 2012
Limitations and caveats
This was an explorative study to collect data for a subsequent controlled trial and therefore no hypothesis testing was performed. The size of the efficacy population (N=7) is too small to detect any statistically significant changes.

Participant flow

Asthmatic patients, aged at least 18 years, suffering from severe persistent asthma, having nocturnal symptoms and receiving treatment with oral glucocorticoids were recruited from Hôpital Bichat between July 2008 and March 2010.

Run-in Period
Participant flow — Run-in Period
MilestoneSafety Population
Started12
Completed7
Not completed5
Withdrew: Adverse event1
Withdrew: Asthma exacerbation1
Withdrew: Violation of inclusion/exclusion criteri3
Treatment Period
Participant flow — Treatment Period
MilestoneSafety Population
Started7
Completed7
Not completed0

Outcome measures

PrimaryTotal Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment

Variation in the total number of nocturnal awakenings during the last 2 weeks of run-in treatment with Cortancyl and the last 2 weeks of treatment with Lodotra.

Time frame:
4 weeks and 8 weeks
Reported as:
Mean · number of nocturnal awakenings
Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment
number of nocturnal awakeningsLodotraCortancyl
Total Number of Nocturnal Awakenings During the Last 2 Weeks of Treatment2.1 ± 4.4110.0 ± 5.45
Statistical analysis
  • Lodotra vs Cortancyl · Other · Mean difference (final values): -7.9 · 95% CI -13.5 to -2.2As this was an explorative study, no hypothesis testing was performed. All analyses were descriptive.

Adverse events

Collected over Adverse event data were collected from the time the patient gave informed consent until the end of the follow-up visit or 30 days after last study drug administration, whichever occurred later.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lodotra—0/7 (0%)6/7 (85.7%)
Cortancyl—1/12 (8.3%)7/12 (58.3%)
Most frequent serious events
Most frequent serious events
EventLodotraCortancyl
asthmaRespiratory, thoracic and mediastinal disorders0/71/12
arterial thrombosisVascular disorders0/71/12
Most frequent other events
Showing 10 of 18
Most frequent other events
EventLodotraCortancyl
asthmaRespiratory, thoracic and mediastinal disorders2/72/12
insomniaPsychiatric disorders2/70/12
bronchitisInfections and infestations0/73/12
arthralgiaMusculoskeletal and connective tissue disorders1/70/12
coughRespiratory, thoracic and mediastinal disorders1/70/12
dyspnoeaRespiratory, thoracic and mediastinal disorders1/70/12
hernial eventrationGastrointestinal disorders1/70/12
influenza like illnessGeneral disorders1/71/12
menstrual disorderReproductive system and breast disorders1/70/12
oedemaGeneral disorders1/70/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Safety Population
<=18 years0
Between 18 and 65 years11
>=65 years1
Age, Continuous
Age, Continuous(years)Safety Population
Mean48.9 ± 14.40
Sex: Female, Male
Sex: Female, Male(Participants)Safety Population
Female11
Male1
Region of Enrollment
Region of Enrollment(participants)Safety Population
France12
08

Study locations

1 site
  • Hôpital Bichat
    Paris, 75018, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2008
First posted
May 29, 2008
Start
Jun 2008
Primary completionActual
Mar 2010
CompletionActual
May 2010
Results first posted
Dec 28, 2012
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00686335
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 29, 2008
Start date
Jun 2008
Primary completion
Mar 2010
Completion
May 2010
Results posted
Dec 28, 2012
Last update
Dec 17, 2024

Study contacts

Michel MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion